MTVA — MetaVia Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1638287 ·
Last close
$1.66
Market Cap
$10.94M
52W High
$14.85
52W Low
$0.97
ADV30
81,357
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,385,000 | -5,316,000 | 13,271,000 | 12,634,000 | 6,449,000 |
| Mar 2026 | 0 | — | -4,025,000 | -3,823,000 | 14,388,000 | 13,731,000 | 5,315,000 |
| Dec 2025 | 0 | — | -2,046,000 | -1,930,000 | 11,123,000 | 10,278,000 | 5,790,000 |
| Sep 2025 | 0 | — | -3,475,000 | -3,377,000 | 14,765,000 | 14,277,000 | 8,434,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,835,000
Investing CF
$-2,000
Financing CF
$10,880,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.10
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-157,969,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-14,931,000
Pretax Income TTM
$-14,446,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,708,000 | -12,973,000 | 11,123,000 | 5,790,000 | 5,333,000 | -15,701,000 |
| Dec 2024 | 0 | -28,809,000 | -27,592,000 | 16,260,000 | 8,329,000 | 7,931,000 | -24,710,000 |
| Dec 2023 | 0 | -15,886,000 | -12,470,000 | 22,781,000 | 6,096,000 | 16,685,000 | -10,799,000 |
| Dec 2022 | 0 | -11,418,000 | -13,967,000 | 33,534,000 | 11,784,000 | 21,750,000 | -11,712,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | $10.94M | $7.25 | — |
| GDTC | CytoMed Therapeutics Ltd | $11.30M | $0.95 | — |
| SCNX | Scienture Holdings, Inc. | $11.37M | $0.28 | — |
| ENLV | Enlivex Ltd. | $10.46M | $0.60 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.64M | $2.63 | — |
News headlines (Yahoo Finance, 1h cache)
MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
2026-09-10 12:25 · Yahoo
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
2026-09-09 12:00 · Yahoo
MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726
2026-08-12 12:20 · Yahoo
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 20:05 · Yahoo
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
2026-07-09 12:31 · Yahoo
OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz
2026-06-30 14:42 · Yahoo
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
2026-06-08 12:31 · Yahoo
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726
2026-05-28 10:54 · Yahoo
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
2026-05-27 12:31 · Yahoo
MTVA: Multiple Upcoming Presentations to Highlight DA-1726 and Vanoglipel
2026-05-21 13:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.